

IN THE CLAIMS:

B2 Sub C1 10. A method of treatment of a mammalian body comprising administering a medicament effective on a cC1qR binding domain.

Please add the following new claims:

B3 Sub C1 11. The method of treatment wherein the cC1qR is a complement ubiquitin (CUB) domain.

12. The method of Claim 11 wherein the treatment includes administering a medicament effective on a complement ubiquitin (CUB) domain.

13. The method of Claim 12 wherein treatment includes administering to the mammal a therapeutically effective quantity of medicament to effect CUB functionality.

14. The method of Claim 12 wherein treatment includes administering to the mammal a therapeutically effective quantity of medicament to effect CUB functionality in the treatment of conditions selected from the group of initiation and maintenance of inflammation, myocardial infarction, brain ischemia, gut ischemia, rheumatoid arthritis, systemic lupus erythematosus, burns, immune complex and nephritis, the binding of B-amyloid to C1q and opsonisation.

15. The method of Claim 10 wherein the cC1qR binding domain has the sequence selected from the group consisting of SEQ ID NOS 1- 3.

16. A method of treatment of a mammalian body comprising administering a medicament manufactured using a cC1qR binding domain inhibitor.

17. The method of treatment of Claim 16 wherein the inhibitor of the cC1qR binding domain inhibits CUB functionality.

18. The method of treatment of claim 16 wherein the cC1qR binding domain inhibitor is used for the treatment of complement activation involved in the initiation and maintenance of inflammation.